2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171013
    THR-β agonist 8 2832859-77-3 98%
    THR-β agonist 8 (Compound 1) is an orally active agonist of TRα and TRβ. THR-β agonist 8 is promising for research of thyroid hormone-related diseases.
    THR-β agonist 8
  • HY-171052
    5-HT6R antagonist 5 1220645-15-7
    5-HT6R antagonist 5 (compound 1.2.12(4)) is a potent competitive 5-HT6R antagonist with an IC50 of 4.19 nM. 5-HT6R antagonist 5 can be used for research in various central nervous system (CNS) diseases, cognitive and neurodegenerative diseases.
    5-HT6R antagonist 5
  • HY-171096
    PAR2 modulator-1 2378159-28-3 98%
    PAR2 modulator-1 (Compound C781) is a protease activated receptor type 2 (PAR2) antagonist. PAR2 modulator-1 can specifically inhibit the PAR2-dependent MAPK signaling pathway with an IC50 value of 8.5 μM. PAR2 modulator-1 can block the pain response triggered by PAR2 agonists. PAR2 modulator-1 can be used for the researches of inflammation, immunology and neurological disease, such as chronic pain and asthma.
    PAR2 modulator-1
  • HY-171116
    Kv7.2/Kv7.3 activator-4 1886011-37-5 98%
    Kv7.2/Kv7.3 activator-4 (example 53) is a Kv7.2/Kv7.3 potassium channel activator that can be used in the research of epilepsy, neuropathic pain and other related diseases.
    Kv7.2/Kv7.3 activator-4
  • HY-171216
    GW559090 278598-52-0
    GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a Kd of 0.19 nM for α4β1. GW559090 can effectively block the binding of α4β1 to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with IC50 values of 7.72 and 8.04 nM. GW559090 also inhibits the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) (IC50 = 23 nM). GW559090 can inhibit inflammatory infiltration in the eyes, repair the corneal barrier and restore the function of goblet cells. GW559090 can be used for research of Sjögren's syndrome associated dry eye.
    GW559090
  • HY-171232
    Jimscaline 890309-57-6 98%
    Jimscaline (compound R-(-)2) is a 5-HT2A agonist and mescaline analogue that can be utilized in neurological research.
    Jimscaline
  • HY-171234
    R-4066 66194-36-3 98%
    R-4066 is an agent which is an analogue of the opioid analgesic Methadone. R-4066 is a highly potent, long-acting analgesic.
    R-4066
  • HY-171235
    5-HT2A antagonist 3 1134815-69-2 98%
    5-HT2A antagonist 3 (Formula (III)) is a 5-HT2A receptor antagonist and inverse agonist with a pIC50 of 8.7 and a pKi of 9. 5-HT2A antagonist 3 can be utilized in neurological reesearch.
    5-HT2A antagonist 3
  • HY-171253
    Clotizolam 54123-06-7 98%
    Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects.
    Clotizolam
  • HY-171298
    CK1δ-IN-10 2765374-31-8 98%
    CK1δ-IN-10 (Compound 85) is the inhibitor for casein kinase 1 that inhibits CK1δ (CSNKID) with IC50 of 0.255 μM.
    CK1δ-IN-10
  • HY-171317
    SMARt751 1616370-52-5 99.99%
    SMARt751 targets the transcriptional regulatory factor VirS, inhibits its DNA binding ability, upregulates the mymA operon expression, thereby activating Ethionamide (HY-B0276), enhancing the antimicrobial activity of Ethionamide. SMARt751 enhances the antibacterial activity of Ethionamide against M. tuberculosis, reverses the Ethionamide resistance. SMARt751 improves the antibacterial effect of Ethionamide and reduces its effective dose in mouse models.
    SMARt751
  • HY-171333
    TMEM16A modulator-1 2367645-32-5
    TMEM16A modulator-1 (compound 36) is a positive modulator of the calcium-activated chloride channel (CaCC) TMEM16A. TMEM16A modulator-1 can be used for TMEM16A-related diseases research, particularly respiratory diseases and conditions.
    TMEM16A modulator-1
  • HY-171335
    ST-115 1840873-90-6
    ST-115 is a highly potent and very specific aminopeptidase P2 inhibitor. ST-115 can be used in the research of ischemic stroke.
    ST-115
  • HY-171656
    G721-0282 946378-12-7 99.96%
    G721-0282 is an orally active CHI3L1 inhibitor. G721-0282 can reduce the expression of inflammatory proteins and cytokines. G721-0282 inhibits the activation of the NF-κB signaling pathway. G721-0282 inhibits neuroinflammation and reduces anxious behavior. G721-0282 significantly inhibits the proliferation of osteosarcoma (OS) cells by suppressing the STAT3 signaling pathway. G721-0282 induces OS cell apoptosis by upregulating pro-apoptotic protein levels and downregulating anti-apoptotic protein levels. G721-0282 can be used for researches on neuroinflammatory conditions and cancer.
    G721-0282
  • HY-171758
    BU72 173265-76-4
    BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC50 values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence.
    BU72
  • HY-171778
    QLS-81 2835455-57-5
    QLS-81 is a Nav1.7 channel inhibitor (IC50: 1.5 μM). QLS-81 has significant analgesic activity and can relieve neuropathic and inflammatory pain. QLS-81 exerts frequency-dependent inhibitory effects by inhibiting the inactivated state of Nav1.7 channels. QLS-81 can be used in the study of chronic pain.
    QLS-81
  • HY-171790
    W-2451 37795-71-4
    W-2451 (NSC 294839) is a selective serotonin 5-HT2 receptor antagonist. W-2451 is promising for research of neurological disorders.
    W-2451
  • HY-171791
    WAY-166818 142629-43-4 98%
    WAY-166818 (WAY-818) is a synthetic nonsteroidal estrogen that is a selective agonist of ERβ.
    WAY-166818
  • HY-171794
    AZD1134 442548-99-4
    AZD1134 is an orally active, brain-penetrant and highly selective 5-HT1B receptor antagonist with IC50 values of 2.9 nM (human) and 0.108 nM (guinea pig), respectively. AZD1134 increases synaptic serotonin levels in guinea pigs. AZD1134 is promising for research of psychiatric disorders, such as depression and anxiety.
    AZD1134
  • HY-171801
    PROTAC LRRK2 Degrader-1 3031514-69-6 98%
    PROTAC LRRK2 Degrader-1 (compound 18) is a leucine-rich repeat kinase 2 (LRRK2) PROTAC degrader with an IC50 value less than 10 nM. PROTAC LRRK2 Degrader-1 can be used in the research of Parkinson's disease.
    PROTAC LRRK2 Degrader-1
Cat. No. Product Name / Synonyms Application Reactivity